Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat + Fulvestrant After CDK4/6 Inhibitor in HR+/HER2- Advanced Breast Cancer
ChiCTR2500114131Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of entinostat and fulvestrant in breast cancer, sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Progression-free survival. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
entinostatfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500114131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114131.